(800) 526-OPYS Pay my bill Member login
logo
OPYS 10 years
  • Hospital Solutions
    • Emergency Medicine
    • Hospital Medicine
    • Telemedicine
    • Urgent Care
    • Post Acute Care
    • Correctional Medicine
    • Locum Tenens
  • Join our Team
    • Physicians
    • Advanced Practitioners
    • Career Opportunities
  • About OPYS
    • Experienced Group
    • Metrics & Outcomes
    • Throughout the US
    • Quality Patient Care
    • Clinical Performance
    • Qualified Providers
    • Company Profile
    • Leadership Team
    • Mission Statement
    • Reviews
  • News
  • Contact Us

What are the Data on Ivermectin for COVID-19?

Home > COVID-19 > What are the Data on Ivermectin for COVID-19?

What are the Data on Ivermectin for COVID-19?

January 5, 2022

Ivermectin, a medication that has long been approved by the U.S. Food and Drug Administration (FDA) and World Health Organization (WHO) to fight parasites and treat worm infections, has been a topic of controversy during the COVID-19 pandemic. Some experts have argued that public messages about ivermectin could lead people to use ivermectin that is formulated for animals to prevent or treat COVID-19 – an exercise that would of course be dangerous. Others have encouraged more research into the safety and efficacy of ivermectin in COVID-19 in response to data suggesting that the drug may be effective in combating COVID-19,

A new meta-analysis published in the American Journal of Therapeutics has reviewed evidence surrounding the use of ivermectin in COVID-19 and sheds light on the value the drug may bring in the context of this disease and the pandemic. The results showed that compared to those who took no ivermectin, those who took ivermectin had a reduced risk of death.There were conflicting results about whether ivermectin was beneficial as a treatment, but severe adverse events in those taking ivermectin were rare.

When looked at comprehensively, the authors concluded that the data around ivermectin and COVID-19 provides moderate-certainty evidence that COVID-19 deaths could be largely reduced with the use of ivermectin. Specifically, the authors argue that intervening early in the course of COVID-19 disease with ivermectin could reduce the number of people who’s infection progresses to severe disease.

The authors conclude that given the low cost, favorable safety profile, and evidence for the potential value of ivermectin in COVID-19, it is possible that ivermectin could have a significant influence on the pandemic. More research on the effects of ivermectin in COVID-19 will help to clarify if and when it is appropriate for physicians to prescribe the drug to fight the pandemic.

Additional information can also be found in the CDC’s most recent update: COVID-19 Treatment Guidelines

 

Reference

Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American Journal of Therapeutics. 2021;28(4):e434. doi:10.1097/MJT.0000000000001402

 

Filed Under: Best Practice, COVID-19, Patient Care, Physician Services News, Public Health Tagged With: CDC, Coronavirus, COVID-19, Health care, hospital based physicians, Medications, patient care, Symptoms of coronavirus

Search

Categories

  • Best Practice
  • Cardiologists
  • COVID-19
  • Emergency Physicians
  • General
  • Health Technology
  • Hospital Physicians
  • Hospitalists
  • New Job Opportunities
  • Nurses
  • Patient Care
  • Physician Job
  • Physician Services News
  • Public Health
  • Reimbursement
  • Telehealth Blog Series
  • Women's Health

Archives

  • May 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • April 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • September 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • December 2017
  • March 2017
  • June 2016
  • August 2015
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011

We’d Love to Hear From You,
Get In Touch With Us!

logo

Since 2012, providing quality, efficient, patient-centered healthcare through experienced medical leadership, communication, and collaboration in the provision of hospital-based physician outsourcing services.

Our Services
  • Emergency Medicine
  • Hospital Medicine
  • Telemedicine
  • Urgent Care
  • Post Acute Care
  • Correctional Medicine
OPYS Advantage
  • Our Team
  • Investor Relations
  • Career Opportunities
Contact
Corporate Office 

One Indiana Square, Suite 2060
Indianapolis, IN 46204

Phone: (800) 526-6797
Fax: (800) 456-6148
Email: info@opys.com

Copyright © 2012 - 2022. All rights reserved I Site Map I Privacy Policy I Terms and Use